Meraj Hasan Khan

Dr. Meraj Hasan Khan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SASyed Bilal Ahmad Andrabi
Syed Bilal Ahmad Andrabi
KBKedar Batkulwar
Kedar Batkulwar
SBSantosh D. Bhosale
Santosh D. Bhosale
RMRobert Moulder
Robert Moulder
MKMeraj Hasan Khan
Meraj Hasan Khan
RLRiitta Lahesmaa
Riitta Lahesmaa
Transcriptional repressor, hypermethylated in cancer 1 (HIC1) participates in a range of important biological processes, such as tumor repression, immune suppression, embryonic development and epigenetic gene regulation. Further to these, we previously demonstrated that HIC1 provides a significant contribution to the function and development of regulatory T (Treg) cells. However, the mechanism by which it regulates these processes was not apparent. To address this question, we used affinity-purification mass spectrometry to characterize the HIC1 Interactome in human Treg cells. Altogether 61 high-confidence interactors were identified, including IKZF3, which is a key transcription factor in the development of Treg cells. The biological processes associated with these interacting proteins include protein transport, mRNA processing, non-coding (ncRNA) transcription and RNA metabolism. The results revealed that HIC1 is part of a FOXP3-RUNX1-CBFB protein complex that regulates Treg signature genes thus improving our understanding of HIC1 function during early Treg cell differentiation. Highlights: Systematic characterization of HIC1 interactome in regulatory T cells by Affinity Purification-Mass Spectrometry HIC1 binds to the RUNX1 promoter and regulates its expression HIC1-a part of FOXP3-RUNX1-CBFB transcriptional complex Graphical

24 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
RMRezvan Mobasseri
Rezvan Mobasseri
AGAli Ghiaseddin
Ali Ghiaseddin
MKMeraj Hasan Khan
Meraj Hasan Khan
PWPatrick Wagner
Patrick Wagner
NDNeda Dadgar
Neda Dadgar
The success of regenerative biomaterials depends not simply on biocompatibility but also on their ability to direct coordinated interactions between immune and stromal compartments that ultimately determine tissue repair, integration, or fibrosis. Rather than viewing inflammation and fibrosis as independent outcomes, this review presents a design framework that links engineered material properties to sequential immune activation, stromal remodeling, and long-term tissue function. We describe how material chemistry, architecture, mechanical properties, degradation behavior, surface modification, and spatiotemporal delivery of bioactive signals shape innate immune sensing, macrophage state transitions, adaptive immune regulation, and the macrophage–fibroblast axis. We further discuss how these interconnected processes regulate extracellular matrix remodeling, vascular adaptation, and fibrotic capsule formation, emphasizing that tissue fate emerges from the coordination of immune and stromal responses rather than from modulation of any single pathway. Drawing on this evidence, we propose a four-layer conceptual framework that organizes engineered inputs, biological processes, stromal responses, and tissue-level outcomes. Rather than functioning as a predictive model, the framework is intended as an evidence-mapping and experimental-design tool that makes explicit where causal links are directly supported, where they are inferred, and where they remain untested. We identify key translational gaps—including study heterogeneity, incomplete stromal and functional assessment, limited clinical validation, and insufficient longitudinal profiling—and propose practical priorities for multiparameter stromal analysis, high-dimensional myeloid phenotyping, intermediate mechanistic models, and application-relevant functional endpoints.

2 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMohd Moin Khan
Mohd Moin Khan
ISInna Starskaia
Inna Starskaia
EREmilie Rydgren
Emilie Rydgren
SJSini Junttila
Sini Junttila
JSJohannes Smolander
Johannes Smolander
UKUbaid Ullah Kalim
Ubaid Ullah Kalim
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) driven by pathogenic T cell-mediated inflammation. Fingolimod (FTY720), an approved therapy for MS, is an established activator of protein phosphatase 2A (PP2A). However the contribution of PP2A in autoimmune neuroinflammation remains incompletely understood. Here, we addressed this question using experimental autoimmune encephalomyelitis (EAE), a murine model of MS, in mice carrying a genetic disruption of the locus encoding cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous inhibitor of PP2A. Mice with disruption of the CIP2A locus, the knock out (KO) mice, exhibited attenuated EAE severity compared with wild-type (WT) controls. Histological and flow-cytometric analyses revealed markedly reduced infiltration of mononuclear cells, including CD4 + and CD4 + CXCR6 + encephalitogenic T cells, in the CNS of diseased KO mice. Reduced numbers of these T cell populations were also observed in peripheral lymphoid organs of the Cip2a-deficient mice during EAE, while T cell abundance was comparable under steady-state conditions, suggesting impaired activation-induced expansion rather than altered homeostasis or migration. Single-cell RNA sequencing of CNS and lymph node immune cells revealed changes in cell-type abundance and gene expression. Notably, Il17a expression was reduced in CNS CD8+ T cells and showed a similar trend in γδ T cells. Together, our findings reveal that genetic disruption at the CIP2A locus attenuates EAE, possibly by limiting the expansion and accumulation of encephalitogenic T cell populations in CNS. These results identify the CIP2A locus as a previously unrecognized regulator of T cell-driven autoimmune neuroinflammation and provide new insights into mechanisms that restrain pathogenic T cell responses during EAE.